作者
Faith Matcham, C Barattieri di San Pietro, Viola Bulgari, G De Girolamo, R Dobson, Hans Eriksson, AA Folarin, Josep Maria Haro, Maximilian Kerz, Femke Lamers, Qingqin Li, NV Manyakov, David C Mohr, Inez Myin-Germeys, Vaibhav Narayan, Penninx Bwjh, Yatharth Ranjan, Zulqarnain Rashid, Aki Rintala, Sara Siddi, Sara Katherine Simblett, T Wykes, Matthew Hotopf, RADAR-CNS consortium Sonia DiFrancesco Katie White Alina Ivan Ashley Polhemus Jose Ferrao Michiel Ringkjøbing-Elema Francesco Nobilia Wolfgang Viechtbauer Sjaak Peelen Zulqarnain Rashid Janneke Boere Nicholas Cummins Nick Meyer
发表日期
2019/12
期刊
BMC psychiatry
卷号
19
页码范围
1-11
出版商
BioMed Central
简介
Background
There is a growing body of literature highlighting the role that wearable and mobile remote measurement technology (RMT) can play in measuring symptoms of major depressive disorder (MDD). Outcomes assessment typically relies on self-report, which can be biased by dysfunctional perceptions and current symptom severity. Predictors of depressive relapse include disrupted sleep, reduced sociability, physical activity, changes in mood, prosody and cognitive function, which are all amenable to measurement via RMT. This study aims to: 1) determine the usability, feasibility and acceptability of RMT; 2) improve and refine clinical outcome measurement using RMT to identify current clinical state; 3) determine whether RMT can provide information predictive of depressive relapse and other critical outcomes.
Methods
RADAR-MDD is a multi …
学术搜索中的文章
F Matcham, C Barattieri di San Pietro, V Bulgari… - BMC psychiatry, 2019